DGAP-News

Novavax Reports Fourth-Quarter and Year-End 2013 Financial Results and Initiation of Phase 1/2 Clinical Trial of Its H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M(TM)

DGAP-News: Novavax, Inc. /
Novavax Reports Fourth-Quarter and Year-End 2013 Financial Results and
Initiation of Phase 1/2 Clinical Trial of Its H7N9 Avian Influenza VLP
Vaccine Candidate With Matrix-M(TM)

10.03.2014 / 21:19

---------------------------------------------------------------------

GAITHERSBURG, Md., 2014-03-10 21:18 CET (GLOBE NEWSWIRE) --
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused
on the discovery, development and commercialization of recombinant nanoparticle
vaccines and adjuvants, today reported its financial results for the fourth
quarter and year ended December 31, 2013 and announced the initiation of a
Phase 1/2 clinical trial of its H7N9 avian influenza VLP vaccine candidate with
its proprietary Matrix-M adjuvant. The trial is enrolling 610 healthy subjects
to evaluate the safety and immunogenicity of this vaccine and adjuvant.

Novavax Business Highlights

2013 Achievements:

-- Reported data from two RSV F-protein nanoparticle vaccine trials, one in
330 women of childbearing age and the other in 220 elderly subjects,
demonstrating strong immunogenicity of the RSV vaccine candidate;
-- Demonstrated in the RSV elderly subject trial that the vaccine could be
administered concurrently with a seasonal influenza vaccine to elicit
potentially protective levels of antibodies to both vaccine targets;
-- Initiated our H7N9 avian influenza VLP vaccine candidate program in April
and published the industry's first H7N9 vaccine human clinical trial data
showing highly protective levels of antibodies following vaccination in the
December 26th issue of the New England Journal of Medicine;
-- Acquired Novavax AB (previously Isconova AB) and its saponin-based adjuvant
Matrix-M to support Novavax' vaccine programs; and
-- Completed a successful $100 million secondary stock offering.

2014 Recent Events:

-- Extended the contract for Advanced Development of Recombinant Influenza
Products and Pandemic Preparedness with HHS BARDA; and
-- Initiated a U.S.-based Phase 1/2 clinical trial of H7N9 avian influenza VLP
vaccine candidate with Matrix-M, enrolling 610 healthy adult subjects
between 18 and 64 years old, under the Company's HHS BARDA contract.

2014 Anticipated Events:

-- Release of top-line data from the ongoing Phase 2 clinical trial of the RSV
F protein nanoparticle vaccine candidate in women of childbearing age in
the second quarter of 2014;
-- Release of top-line data from the recently initiated Phase 1/2 clinical